Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1995;22(1):40–43.

Use of amiodarone in the postmyocardial infarction patient.

E Ozdil 1, T A Carlson 1, A Massumi 1
PMCID: PMC325209  PMID: 7787469

Abstract

Amiodarone appears to be an effective antiarrhythmic agent for reducing mortality in the postmyocardial infarction patient with ventricular ectopic activity. Such activity has long been recognized to have an adverse effect on prognosis after acute myocardial infarction. When a strong correlation between ectopic activity and left ventricular dysfunction was demonstrated, ventricular ectopic activity was thought to be a consequence of underlying myocardial damage. However, ventricular ectopic activity is now considered to be an independent risk factor for mortality after myocardial infarction. Because of the basic premise that a positive correlation existed between arrhythmia suppression and improved survival, it had been common practice to use antiarrhythmic agents to treat asymptomatic ventricular ectopic activity in the postinfarction patient. After the results of the Cardiac Arrhythmia Suppression Trial (CAST) were released, this practice was largely abandoned. In the post-CAST era, however, amiodarone has appeared to improve survival in patients who have sustained myocardial infarctions. In this report, we briefly review the pharmacology of amiodarone and discuss the results of relevant clinical trials. Large, multicenter trials currently under way may clarify some of the unanswered questions surrounding the use of this promising antiarrhythmic agent in postmyocardial infarction patients.

Full text

PDF
40

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bigger J. T., Jr, Fleiss J. L., Kleiger R., Miller J. P., Rolnitzky L. M. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984 Feb;69(2):250–258. doi: 10.1161/01.cir.69.2.250. [DOI] [PubMed] [Google Scholar]
  2. Burkart F., Pfisterer M., Kiowski W., Follath F., Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol. 1990 Dec;16(7):1711–1718. doi: 10.1016/0735-1097(90)90324-i. [DOI] [PubMed] [Google Scholar]
  3. Cairns J. A., Connolly S. J., Gent M., Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation. 1991 Aug;84(2):550–557. doi: 10.1161/01.cir.84.2.550. [DOI] [PubMed] [Google Scholar]
  4. Ceremuzynski L., Kleczar E., Krzeminska-Pakula M., Kuch J., Nartowicz E., Smielak-Korombel J., Dyduszynski A., Maciejewicz J., Zaleska T., Lazarczyk-Kedzia E. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol. 1992 Nov 1;20(5):1056–1062. doi: 10.1016/0735-1097(92)90357-s. [DOI] [PubMed] [Google Scholar]
  5. Chamberlain D. A., Jewitt D. E., Julian D. G., Campbell R. W., Boyle D. M., Shanks R. G. Oral mexiletine in high-risk patients after myocardial infarction. Lancet. 1980 Dec 20;2(8208-8209):1324–1327. doi: 10.1016/s0140-6736(80)92395-8. [DOI] [PubMed] [Google Scholar]
  6. Greene H. L. The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. Prog Cardiovasc Dis. 1989 Mar-Apr;31(5):319–354. doi: 10.1016/0033-0620(89)90029-7. [DOI] [PubMed] [Google Scholar]
  7. Haworth R. A., Goknur A. B., Berkoff H. A. Inhibition of ATP-sensitive potassium channels of adult rat heart cells by antiarrhythmic drugs. Circ Res. 1989 Oct;65(4):1157–1160. doi: 10.1161/01.res.65.4.1157. [DOI] [PubMed] [Google Scholar]
  8. Heger J. J., Prystowsky E. N., Jackman W. M., Naccarelli G. V., Warfel K. A., Rinkenberger R. L., Zipes D. P. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981 Sep 3;305(10):539–545. doi: 10.1056/NEJM198109033051002. [DOI] [PubMed] [Google Scholar]
  9. Kudenchuk P. J., Pierson D. J., Greene H. L., Graham E. L., Sears G. K., Trobaugh G. B. Prospective evaluation of amiodarone pulmonary toxicity. Chest. 1984 Oct;86(4):541–548. doi: 10.1378/chest.86.4.541. [DOI] [PubMed] [Google Scholar]
  10. Martin W. J., 2nd, Rosenow E. C., 3rd Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest. 1988 May;93(5):1067–1075. doi: 10.1378/chest.93.5.1067. [DOI] [PubMed] [Google Scholar]
  11. Mason J. W., Hondeghem L. M., Katzung B. G. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res. 1984 Sep;55(3):278–285. doi: 10.1161/01.res.55.3.278. [DOI] [PubMed] [Google Scholar]
  12. McGovern B., Garan H., Kelly E., Ruskin J. N. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 1983 Jul 16;287(6386):175–180. doi: 10.1136/bmj.287.6386.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Morady F., Sauve M. J., Malone P., Shen E. N., Schwartz A. B., Bhandari A., Keung E., Sung R. J., Scheinman M. M. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol. 1983 Nov 1;52(8):975–979. doi: 10.1016/0002-9149(83)90515-5. [DOI] [PubMed] [Google Scholar]
  14. Mukharji J., Rude R. E., Poole W. K., Gustafson N., Thomas L. J., Jr, Strauss H. W., Jaffe A. S., Muller J. E., Roberts R., Raabe D. S., Jr Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol. 1984 Jul 1;54(1):31–36. doi: 10.1016/0002-9149(84)90299-6. [DOI] [PubMed] [Google Scholar]
  15. Nademanee K., Hendrickson J. A., Cannom D. S., Goldreyer B. N., Singh B. N. Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J. 1981 Jun;101(6):759–768. doi: 10.1016/0002-8703(81)90613-x. [DOI] [PubMed] [Google Scholar]
  16. Nademanee K., Piwonka R. W., Singh B. N., Hershman J. M. Amiodarone and thyroid function. Prog Cardiovasc Dis. 1989 May-Jun;31(6):427–437. doi: 10.1016/0033-0620(89)90017-0. [DOI] [PubMed] [Google Scholar]
  17. Nicklas J. M., McKenna W. J., Stewart R. A., Mickelson J. K., Das S. K., Schork M. A., Krikler S. J., Quain L. A., Morady F., Pitt B. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J. 1991 Oct;122(4 Pt 1):1016–1021. doi: 10.1016/0002-8703(91)90466-u. [DOI] [PubMed] [Google Scholar]
  18. Nishimura M., Follmer C. H., Singer D. H. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1989 Nov;251(2):650–659. [PubMed] [Google Scholar]
  19. Pfisterer M. E., Kiowski W., Brunner H., Burckhardt D., Burkart F. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation. 1993 Feb;87(2):309–311. doi: 10.1161/01.cir.87.2.309. [DOI] [PubMed] [Google Scholar]
  20. Pfisterer M., Kiowski W., Burckhardt D., Follath F., Burkart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol. 1992 Jun 1;69(17):1399–1402. doi: 10.1016/0002-9149(92)90889-7. [DOI] [PubMed] [Google Scholar]
  21. Polster P., Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol. 1976 Jan 15;25(2):131–134. doi: 10.1016/0006-2952(76)90279-3. [DOI] [PubMed] [Google Scholar]
  22. Rakita L., Sobol S. M., Mostow N., Vrobel T. Amiodarone pulmonary toxicity. Am Heart J. 1983 Oct;106(4 Pt 2):906–916. doi: 10.1016/0002-8703(83)90015-7. [DOI] [PubMed] [Google Scholar]
  23. Rosenbaum M. B., Chiale P. A., Haedo A., Lázzari J. O., Elizari M. V. Ten years of experience with amiodarone. Am Heart J. 1983 Oct;106(4 Pt 2):957–964. doi: 10.1016/0002-8703(83)90022-4. [DOI] [PubMed] [Google Scholar]
  24. Rosenbaum M. B., Chiale P. A., Halpern M. S., Nau G. J., Przybylski J., Levi R. J., Lázzari J. O., Elizari M. V. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934–944. doi: 10.1016/0002-9149(76)90807-9. [DOI] [PubMed] [Google Scholar]
  25. Ruskin J. N., McGovern B., Garan H., DiMarco J. P., Kelly E. Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med. 1983 Nov 24;309(21):1302–1306. doi: 10.1056/NEJM198311243092107. [DOI] [PubMed] [Google Scholar]
  26. Shaikh N. A., Downar E., Butany J. Amiodarone--an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol Cell Biochem. 1987 Aug;76(2):163–172. doi: 10.1007/BF00223481. [DOI] [PubMed] [Google Scholar]
  27. Singh B. N., Vaughan Williams E. M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657–667. doi: 10.1111/j.1476-5381.1970.tb09891.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wilson J. S., Podrid P. J. Side effects from amiodarone. Am Heart J. 1991 Jan;121(1 Pt 1):158–171. doi: 10.1016/0002-8703(91)90969-o. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES